Search filters

Filters
Clear All

Phase

  • 4
  • 3
  • 3
  • 6
  • 2
  • 43
  • 60
  • 38
  • 1
  • 3
  • 57

Found 61 Menstruation trials

A listing of Menstruation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years and younger
All genders
This is a 2-part, open-label study in approximately 9 adults with oHCM. Part A of the study consists of 3 cohorts of approximately 3 participants each administered a single dose of EDG-7500. Part B of the study is an optional multiple-dose treatment period in which approximately 9 participants will receive …
 Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of EGPA
18-90 years
All genders
Phase 2
The main purpose of this study is to learn how well the investigational drug NS-229 works and how safe NS-229 is compared with placebo.  An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) to treat EGPA.   Participants could be in the …
99 years and younger
All genders
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of repeat doses of IgPro20 in subjects with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome). Eligible subjects will be randomized in a 2:1 ratio to receive subcutaneous (SC) infusions of IgPro20 …
99 years and younger
All genders
PROOF-HD is a placebo-controlled (double blind) multicenter Phase 3 trial of Pridopidine in Huntington Disease patients. Recruitment: 480 participants at 60 sites, a target of 8 participants per site. Procedures include administration of study drug or placebo in tablet form twice daily for a period of 67-80 weeks with option …
99 years and younger
All genders
To document the long-term safety and tolerability profile of osilodrostat in routine clinical practice over a 3 year follow up period in patients with endogenous Cushing's Syndrome. The study population is male and females 18 years or greater who are being treated with osilodrostat.The primary data source will be the …
99 years and younger
All genders
The INTEGRA D study will evaluate the safety and efficacy of the CCM D System in patients with heart failure symptoms despite being on GDMT and have an LVEF 40%.The This is designed as a single arm, prospective, multicenter study of 300 subjects that will establish that the device can …
99 years and younger
All genders
The objectives of the study are:To investigate demographic, clinical, genetic, and environmental factors that contribute to variability in analgesic response to ibuprofen.To compare the inflammatory profile and neutrophil phenotypes between patients who use supplemental opioids and those who do not.To establish a well-phenotyped cohort of subjects, with biobanked samples, that …
99 years and younger
All genders
Phase 2
The research study is being conducted to help physicians understand if apremilast, an oral medication, is effective in treating recurrent oral erythema multiforme (EM). Study consists of four research study visits (weeks 0,6. 12, 24, 36) and completion of a daily treatment diary during the 24 week tratment period. Week …
 Harnessing Hormonal Variation to Probe Neural Mechanisms of OCD and Symptom Reduction by EX/RP
18-45 years
All genders
Studies show that hormones affect the brain’s fear extinction network, which is relevant for therapy involving exposure and ritual prevention (EX/RP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX/RP to women during different phases in their menstrual cycle to determine the effects of hormones on the …
99 years and younger
All genders
Phase 2
Compare brain fMRI response to injectable extended-release buprenorphine (Brixadi, XR-BUP) and naltrexone (XR-NTX, Vivitrol) Our primary outcome combines adherence to treatment and the frequency of illicit opioid use during treatment. The primary outcome is a binary indicator of treatment success: Participants who provide 2 weekly UDS positive for opioids or …